Abstract:675 Background: Differentiating passenger and driver mutations of oncogenesis is essential in understanding disease biology and developing biomarkers that use genomic mutations for diagnosis or prognostication. Accumulating research shows normal urothelium harbors many mutations commonly reported in molecular profiling of urothelial carcinoma. This is especially true of NMIBC. Here, genetic profiling of the mutational landscape of pathologic NMIBC tumors (pNMIBC) was performed and compared to matched pathologically benign urothelial tissue (pBT) to determine the frequency of passenger mutations. Methods: From a prospective observational cohort, 9 patients with high-risk NMIBC and pBT on repeat TURBT were identified. Somatic mutational profiles of the index tumor (pNMIBC) and subsequent pBT of each patient was performed via PredicineWES+ whole exome sequencing. Somatic variants were identified using the Predicine DeepSea in-house algorithm as previously described. Briefly, non-synonymous variants are captured and probabilistically annotated as germline vs. somatic in comparison with matched germline PBMC WES+ sequencing. NS somatic mutations observed in pBT were compared to those in pNMIBC to evaluate for putative passenger versus driver mutations. Results: A median of 236 mutations (IQR:100-732) were detected for pNMIBC compared to 37 (IQR: 5-80) in the pBT group (p=0.018). The number of genes with likely somatic mutations in pNMIBC only, both samples, and pBT only, were 2239, 500, and 1, respectively. The most frequently mutated genes in pNMIBC tissue samples were ARID1, TERT, CREBBP, LMTK3 and NCOR1. Notably, both pBT and pNMIBC tissue shared mutations in commonly reported bladder cancer genes such as ARID1A, ERBB2, ATM, ERCC2 and CKDN2A. Somatic mutations in FGFR3, LMTK3, NCOR1, AKAP9, COL11A2, CRYBG3, KMT2A, MCM3AP, PHF3, VPS13A and ZNF28 were present solely in pNMIBC tissue, whereas OVGP1 mutation was exclusive to pBT. Analysis of the functional impact of mutations in genes that are mutated in both benign tissue and pNMIBC offers a deeper understanding of the evolution of bladder cancer via field cancerization. Conclusions: Analysis of the mutational profile of pBT and pNMIBC revealed differential patterns of somatic mutations. Many expected gene mutations were detected in pNMIBC, but surprisingly 18% of all mutated genes were shared between tumor and pathologically benign samples. The fact that only one somatically mutated gene was exclusive to pBT signifies excellent censoring of variants by the DeepSea algorithm. In summary, these preliminary findings suggest that common gene mutations in NMIBC are frequently observed as passenger mutations. This underscores the potential significance of tissue-informed biomarkers tailored to an individual's mutational profile, which may outperform panel assays.

Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive Vs. Muscle Invasive Bladder Cancer: A Pilot Study

A Novel DNA Methylation Signature As an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

Elaboration of a Multisequence MRI-based Radiomics Signature for the Preoperative Prediction of the Muscle-Invasive Status of Bladder Cancer: a Double-Center Study

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non–muscle-invasive bladder cancer using multi-layered –omics studies

Quantitative Identification of Nonmuscle-Invasive and Muscle-Invasive Bladder Carcinomas: A Multiparametric MRI Radiomics Analysis.

Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer

Proteomic analysis of non‐muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment

Real-world Study of Urine-Based NGS Liquid Biopsy in Organ Preservation Therapy of Muscle-Invasive Bladder Cancer (MIBC).

Multi-Omics Analysis Identifies the Heterogeneity and Prognosis in Bladder Cancer

UPLC-Q-TOF/MS-based Urine Metabolomics for the Diagnosis and Staging of Bladder Cancer

Spatially resolved metabolomic characterization of muscle invasive bladder cancer by mass spectrometry imaging

Abstract 5062: Serum Microrna Profiling in Non-Muscle Invasive Bladder Cancer

A Robust Immuno-Prognostic Model of Non-Muscle-Invasive Bladder Cancer Indicates Dynamic Interaction in Tumor Immune Microenvironment Contributes to Cancer Progression

Integrating Genetic Alterations and Histopathological Features for Enhanced Risk Stratification in Non-Muscle-Invasive Bladder Cancer

Differential mutation profiles between benign and cancerous urothelium in patients with non-muscle invasive bladder cancer (NMIBC).

A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette–Guérin and Immune Checkpoint Inhibitors

2402P Urine-based Comprehensive Genomic Profiling Reveals Mutational Landscape in Real-World Patients with Bladder Cancer

Transcriptome analysis of low-risk and high-risk non-muscular invasive bladder cancer patients to reveal disease progression related genes.

Robust Prognostic Subtyping of Muscle-Invasive Bladder Cancer Revealed by Deep Learning-Based Multi-Omics Data Integration